Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in MSI-H/dMMR Stage II/III Colorectal Cancer
NCT05118724Phase 2Active, not recruiting
- Sponsor
- AIO-Studien
- Start
- Dec 2021
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in colorectal cancer (CRC), sponsored by AIO-Studien. Started Dec 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05118724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118724.